IMD 0354 is primarily investigated for its potential therapeutic applications, particularly in the field of inflammation and cancer research. It acts as an inhibitor of IκB kinase β (IKKβ), which plays a critical role in the NF-κB signaling pathway. By inhibiting this pathway, IMD 0354 can suppress the production of pro-inflammatory cytokines, making it a candidate for treating inflammatory diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Additionally, its ability to block NF-κB activation has shown promise in cancer research, as NF-κB is often overactive in many types of tumors, contributing to cancer cell survival and resistance to therapy. IMD 0354 has been studied in preclinical models for its potential to enhance the effectiveness of chemotherapy and radiotherapy by sensitizing cancer cells to these treatments. Its anti-inflammatory and anti-cancer properties make it a compound of interest for further development in drug discovery and therapeutic applications.